Since then, Tremelimumab (anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)) and Durvalumab (anti-PDL1) have also been established as ICI therapies for HCC [120]. Here, CTLA4 is linked to hepatocellular carcinoma.